RNAZ Stock Price, TransCode Therapeutics, . Quote, Chart

Market Summary

USD0.44-0.02

Market Closed

-4.35%

RNAZ Stock Price

View Fullscreen

RNAZ RSI Chart

RNAZ Valuation

Market Cap

9.2M

Price/Earnings (Trailing)

-0.5

Price/Sales (Trailing)

10.02

Price/Free Cashflow

-0.51

RNAZ Price/Sales (Trailing)

RNAZ Profitability

Return on Equity

-1.1K%

Return on Assets

-357.85%

Free Cashflow Yield

-195.89%

RNAZ Fundamentals

RNAZ Revenue

Revenue (TTM)

923.0K

Rev. Growth (Yr)

-92.9%

Rev. Growth (Qtr)

-86.74%

RNAZ Earnings

Earnings (TTM)

-18.5M

Earnings Growth (Yr)

21.28%

Earnings Growth (Qtr)

23.75%

Breaking Down RNAZ Revenue

Last 7 days

-8%

Last 30 days

-31.3%

Last 90 days

-38.7%

Trailing 12 Months

-99.8%

How does RNAZ drawdown profile look like?

RNAZ Financial Health

Current Ratio

1.28

RNAZ Investor Care

Shares Dilution (1Y)

2997.36%

Diluted EPS (TTM)

-105.17

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q2	Q3	Q4
2023	0	1.0M	923.0K
2022	545.7K	813.1K	1.1M
2021	0	0	278.3K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of TransCode Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Sep 28, 2023	dudley robert michael	bought	49,980	0.51	98,000	chief executive officer
Sep 28, 2023	fitzgerald thomas a	bought	25,168	0.51	49,350	chief financial officer
Jun 21, 2023	dudley robert michael	bought	31,818	2.6515	12,000	chief executive officer
Jun 20, 2023	dudley robert michael	bought	16,846	2.5498	6,607	chief executive officer
Jun 09, 2023	dudley robert michael	bought	52,440	2.76	19,000	chief executive officer
Sep 14, 2022	dudley robert michael	bought	23,000	1.15	20,000	chief executive officer
Jun 16, 2022	fitzgerald thomas a	bought	15,240	1.27	12,000	chief financial officer
May 31, 2022	dudley robert michael	bought	3,739	1.8699	2,000	chief executive officer
May 27, 2022	dudley robert michael	bought	51,643	1.8444	28,000	chief executive officer

Which funds bought or sold RNAZ recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 11, 2024	PRIVATE CAPITAL MANAGEMENT LLC	sold off	-100	-13,301	-	-%
Feb 26, 2024	Virtu Financial LLC	sold off	-100	-16,000	-	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	new	-	266	266	-%
Feb 14, 2024	SABBY MANAGEMENT, LLC	sold off	-100	-125,830,000	-	-%
Feb 14, 2024	CAPTRUST FINANCIAL ADVISORS	new	-	8,240	8,240	-%
Feb 14, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	new	-	1,812	1,812	-%
Feb 14, 2024	TANG CAPITAL MANAGEMENT LLC	sold off	-100	-42,232	-	-%
Feb 14, 2024	TWO SIGMA INVESTMENTS, LP	sold off	-100	-8,120	-	-%
Feb 14, 2024	Royal Bank of Canada	unchanged	-	-	-	-%
Feb 14, 2024	CITADEL ADVISORS LLC	new	-	46,458	46,458	-%

Are Funds Buying or Selling RNAZ?

Are funds buying RNAZ calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RNAZ

No. of Funds

Unveiling TransCode Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 15, 2024	medarova zdravka	0.4%	112,077	SC 13G/A
Feb 14, 2024	tang capital partners lp	0.0%	0	SC 13G/A
Feb 13, 2024	lind global fund ii lp	0.1%	26,279	SC 13G/A
Dec 07, 2023	lind global fund ii lp	9.9%	2,500,000	SC 13G
Oct 10, 2023	dudley robert michael	1.9%	227,743	SC 13D/A
Sep 26, 2023	tang capital partners lp	9.99%	354,700	SC 13G
Jun 16, 2023	dudley robert michael	6.0%	111,534	SC 13D/A
Feb 10, 2023	medarova zdravka	12.7%	1,660,739	SC 13G/A
Dec 20, 2022	dudley robert michael	12.7%	1,756,516	SC 13D
Dec 20, 2022	dudley robert michael	10.6%	1,433,369	SC 13G

Recent SEC filings of TransCode Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 23, 2024	8-K	Current Report
Apr 05, 2024	8-K	Current Report
Apr 01, 2024	10-K	Annual Report
Feb 15, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 13, 2024	SC 13G/A	Major Ownership Report
Jan 31, 2024	8-K	Current Report
Jan 22, 2024	8-K	Current Report
Jan 22, 2024	424B4	Prospectus Filed
Jan 18, 2024	S-1/A	Initial Public Offering

Peers (Alternatives to TransCode Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	2.33%	-21.90%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-0.30%	-28.67%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	8.14%	-4.26%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	5.9B	396.6M	-12.04%	-45.12%	-11.11	14.81	425.83%	18.94%
BBIO	4.4B	-	-13.93%	67.39%	-6.74	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.40%	-0.33%	-14.09	12.46	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.72	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-6.74%	-16.88%	-44.6	3.76	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-6.36%	-10.84%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-10.64%	-48.02%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	8.01%	271.09%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-10.76%	0.48%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	76.15%	62.71%	-0.24	2.14	-13.45%	66.37%

TransCode Therapeutics, Inc. News

Latest updates

TransCode Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In null)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2022Q4	2022Q3	2022Q2	2021Q4	2021Q3	2021Q2
Revenue	-86.7%	27.00	206	384	655	447	239	32.00	57.00
Operating Expenses	-23.8%	4,059	5,328	5,527	4,954	4,707	2,986	2,360	356
S&GA Expenses	-65.0%	695	1,985	2,841	1,910	2,087	1,701	1,367	144
R&D Expenses	0.6%	3,364	3,343	2,687	3,044	2,620	1,286	993	212
EBITDA Margin	-	-	-	10.38*	12.73*	16.44*	40.32*	63.36*	50.50*
Interest Expenses	9.0%	12.00	11.00	16.00	15.00	704*	0.50*	333*	42.00
EBT Margin	-	-	-	10.26*	12.60*	16.31*	39.82*	62.42*	48.57*
Net Income	23.7%	-4,041	-5,299	-5,134	-4,289	-4,671	-2,799	-2,329	2,771
Net Income Margin	-2.5%	-20.04*	-19.56*	-16.26*	-18.73*	-24.32*	-24.59*	-	-
Free Cashflow	-62.2%	-5,674	-3,499	-4,047	-4,422	-3,414	-1,686	-3,139	-98.24

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet												(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-49.5%	5,170	10,228	5,882	5,591	7,588	12,016	14,155	18,850	22,938	25,360	1,522	1,055
Current Assets	-52.5%	4,455	9,373	4,893	4,347	7,379	11,570	13,921	18,635	22,732	25,204	540	831
Cash Equivalents	-63.1%	2,768	7,500	3,600	1,623	4,968	8,791	13,438	16,853	20,826	22,500	80.00	828
Net PPE	-20.8%	121	152	179	192	209	210	235	215	206	156	92.00	-
Liabilities	-39.0%	3,529	5,788	3,789	5,827	4,347	3,771	1,727	1,849	2,534	2,205	6,558	4,464
Current Liabilities	-37.6%	3,491	5,598	3,523	5,449	4,347	3,771	1,727	1,849	2,534	2,205	1,533	405
Shareholder's Equity	-63.0%	1,641	4,440	2,092	-	3,241	8,244	12,428	17,001	20,404	23,155	-	-
Retained Earnings	-9.7%	-46,400	-42,300	-37,028	-32,687	-27,870	-22,700	-18,400	-13,800	-10,305	-7,506	-5,176	-3,461
Additional Paid-In Capital	2.8%	48,057	46,768	39,121	32,449	31,111	30,979	30,873	30,775	30,708	30,669	149	66.00
Shares Outstanding	-100.0%	-	10,688	1,951	791	649	649	649	649	8,426	576	232	232

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	-62.1%	-5,674	-3,500	-4,400	-4,500	-4,057	-4,422	-3,372	-3,948	-1,600	-3,067	-76.00	-522	-	-	-
Share Based Compensation	-20.9%	310	392	175	159	131	106	99.00	61.00	39.00	64.00	35.00	48.00	-	-	-
Cashflow From Investing	100.0%	-	-4.61	-18.11	-12.90	-28.21	-	-42.05	-30.66	-82.73	-71.55	-22.24	-75.30	-	-	-
Cashflow From Financing	-86.8%	978	7,391	6,360	1,181	226	-225	-	6.00	9.00	25,560	79.00	-131	-	-	-

RNAZ Income Statement

2023-12-31

STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
STATEMENTS OF OPERATIONS - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Operating expenses
Research and development	$ 12,263,530	$ 10,232,366
General and administrative	7,154,986	8,401,462
Total operating expenses	19,418,516	18,633,828
Operating loss	(19,418,516)	(18,633,828)
Other income
Grant income	923,035	1,080,436
Interest expense	(55,899)	(31,986)
Interest income	5,285	20,410
Total other income	872,421	1,068,860
Net loss	$ (18,546,095)	$ (17,564,968)
Weighted-average common shares outstanding, Basic	179,006	16,222
Weighted-average common shares outstanding, Diluted	179,006	16,222
Net loss per share, Basic	$ (103.61)	$ (1,082.79)
Net loss per share, Diluted	$ (103.61)	$ (1,082.79)

RNAZ Balance Sheet

2023-12-31

BALANCE SHEETS - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash	$ 2,767,598	$ 4,968,418
Grant receivable		360,229
Prepaid expenses and other current assets	1,687,846	2,050,758
Total current assets	4,455,444	7,379,405
Property and equipment, net of depreciation	120,707	208,581
Right-of-use asset, net of amortization	481,694
Security deposit	111,856
Total assets	5,169,701	7,587,986
Current liabilities:
Accounts payable and accrued expenses	3,051,259	4,347,290
Deferred grant income	27,057	0
Short-term lease liability	412,280
Total current liabilities	3,490,596	4,347,290
Long-term lease liability	38,291
Total liabilities	3,528,887	4,347,290
Stockholders' equity:
Preferred stock - $0.0001 par value; 10,000,000 authorized at December 31, 2023 and 2022; - 0 - shares issued and outstanding at December 31, 2023 and 2022
Common stock - $0.0001 par value, 290,000,000 shares authorized at December 31, 2023 and 2022; 627,448 and 16,222 shares issued and outstanding at December 31, 2023 and 2022, respectively	63	2
Additional paid-in capital	48,057,095	31,110,943
Accumulated deficit	(46,416,344)	(27,870,249)
Total stockholders' equity	1,640,814	3,240,696
Total liabilities and stockholders' equity	$ 5,169,701	$ 7,587,986

About TransCode Therapeutics, Inc.

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

CEO	Mr. Robert Michael Dudley
WEBSITE	transcodetherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	19

TransCode Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for TransCode Therapeutics, Inc.? What does RNAZ stand for in stocks?

RNAZ is the stock ticker symbol of TransCode Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of TransCode Therapeutics, Inc. (RNAZ)?

As of Tue Apr 23 2024, market cap of TransCode Therapeutics, Inc. is 9.24 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RNAZ stock?

You can check RNAZ's fair value in chart for subscribers.

What is the fair value of RNAZ stock?

You can check RNAZ's fair value in chart for subscribers. The fair value of TransCode Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of TransCode Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RNAZ so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is TransCode Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether RNAZ is over valued or under valued. Whether TransCode Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact TransCode Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RNAZ.

What is TransCode Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, RNAZ's PE ratio (Price to Earnings) is -0.5 and Price to Sales (PS) ratio is 10.02. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RNAZ PE ratio will change depending on the future growth rate expectations of investors.